Radheshyam Batti, the drug inspector who oversaw Rewa district, has been suspended by the Madhya Pradesh Food and Drug Administration. The order, issued Wednesday, cites serious negligence, arbitrariness and indiscipline tied to the death of Kalpana Mishra, who died during delivery.

Batti's jurisdiction covered Atharva Blood Centre, the facility at the centre of the case. In a separate order the same day, the FDA told Rewa's chief medical and health officer, who also serves as the ex-officio deputy director of FDA, to register a criminal case against the blood centre over what officials describe as irregularities.

Neither order made public so far spells out exactly what those irregularities were, or how they connect to Mishra's death. That detail is presumably sitting inside the inquiry that a committee formed by the National Health Mission director has been running since August 26. The suspension and the FIR direction both flow from that process, along with instructions issued by the state's Public Health and Medical Education Department on September 15.

For now, Batti has been sent to the office of the deputy director, FDA, in Shahdol, for the duration of his suspension. He'll draw a subsistence allowance while he's there, standard procedure for a government employee under suspension rather than dismissal.

The FDA isn't treating this as a closed file. Its state licensing authority and controlling authority have been told to stay in touch with the Rewa drug inspector's office and keep the department updated on whatever action follows. That suggests more paperwork, and possibly more names, could surface once the criminal case against Atharva Blood Centre is formally registered.

What's still missing from the record is any detail on how Mishra died, what role the blood centre is alleged to have played, and whether anyone beyond Batti faces departmental action. No one has been convicted of anything. An FIR is an opening move, not a verdict, and the inquiry that triggered all of this hasn't been made public in full.

The timeline is tight enough to notice. The NHM committee was set up on August 26. The health department's directions came on September 15. The suspension and the FIR order followed within 48 hours of each other. Whether that pace holds once the criminal case actually gets registered, and whether it turns up more than administrative negligence, is the part still unanswered.

Rewa's district health machinery, and whoever ends up named in the FIR against Atharva Blood Centre, will be the next thing to watch here.